Treatment of severe Crohn's disease using antimycobacterial triple therapy - Approaching a cure?

Digestive and Liver Disease

Volumn 34, Issue 1, 2002, Pages 29-38

  Borody, T J ^a   Leis, S ^a   Warren, E F ^a   Surace, R ^a  

^a Center for Digestive Diseases   (Australia)

Author keywords

Crohn's disease; Mycobacterium avium ssp. paratuberculosis

Indexed keywords

ANTIMYCOBACTERIAL AGENT; AZATHIOPRINE; AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CODEINE; MACROLIDE; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; OLSALAZINE; RIFABUTIN; RIFAMYCIN; SALAZOSULFAPYRIDINE; STEROID;

ADOLESCENT; ADULT; ANTIMICROBIAL THERAPY; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; COLONOSCOPY; CONTROLLED STUDY; CROHN DISEASE; DEPIGMENTATION; DISEASE SEVERITY; DRUG MEGADOSE; DRUG RESPONSE; DRY SKIN; FEMALE; FOLLOW UP; HEADACHE; HISTOPATHOLOGY; HUMAN; ILEUM; LEUKOPENIA; MALE; MYCOBACTERIUM PARATUBERCULOSIS; RELAPSE; REMISSION; TREATMENT OUTCOME;

EID: 0036191662     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(02)80056-1     Document Type: Article

References (59)

1. Mycobacterium avium subsp. paratuberculosis as one cause of Crohn's disease
2. The causation of Crohn's disease and treatment with antimicrobial drugs
3. Characteristics of an unclassified Mycobacterium species isolated from patients with Crohn's disease
4. Preliminary report on isolation of patients suffering with Crohn's disease
5. Mycobacterium paratuberculosis DNA in Crohn's disease tissue
6. Polymerase chain reaction detection of Mycobacterium paratuberculosis and Mycobacterium avium subsp. silvaticum in long term cultures from Crohn's disease and control tissues
7. Identification of spheroplast-like agents isolated from tissues of patients with Crohn's disease and control tissues by polymerase chain reaction
8. Specific detection of Mycobacterium paratuberculosis DNA associated with granulomatous tissue in Crohn's disease
9. Detection of Mycobacterium paratuberculosis by polymerase chain reaction in children with Crohn's disease
10. Mycobacterium paratuberculosis in intestinal tissue from patients with Crohn's disease demonstrated by nested primer polymerase chain reaction
11. Mycobacteria in the intestine of Japanese patients with inflammatory bowel disease
12. On the etiology of Crohn's disease
13. Ruminant paratuberculosis (Johne's disease): The current status and future prospects
14. Mycobacterium paratuberculosis cultured from milk and supramammary lymph nodes of infected asymptomatic cows
15. Mycobacterium paratuberculosis: A potential food-borne pathogen?
16. Isolation of Mycobacterium avium subsp. paratuberculosis from breast milk of Crohn's disease patients
17. Characterization of Mycobacterium paratuberculosis p36 antigen and its seroactivities in Crohn's disease
18. Serum antibodies to Mycobacterium paratuberculosis in patients with Crohn's disease
19. Results of multiple diagnostic tests for Mycobacterium avium subsp. paratuberculosis in patients with inflammatory bowel disease and in controls
20. Lack of support for a common etiology in Johne's disease of animals and Crohn's disease in humans
21. Etiological role of mycobacterium in Crohn's disease: An assessment of the literature
22. Dapsone in Crohn's disease
23. Etude critique des effets de la medication antituberculeuse dans une serie de 52 cas de formes severes de la maladie de Crohn
24. Antimycobacterial chemotherapy in two cases of inflammatory bowel disease
25. Quadruple antimycobacterial chemotherapy in Crohn's disease: Results at 9 months of a pilot study in 20 patients
26. Antimycobacterial therapy ineffective in Crohn's disease after a year
27. Controlled trial of rifampicin and ethambutol in Crohn's disease
28. Controlled trial of antimycobacterial therapy in Crohn's disease: Clofazimine versus placebo
29. Antimycobacterial therapy in Crohn's disease: Results of a controlled, double-blind trial with a multiple antibiotic regimen
30. Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease
31. Controlled trial of antituberculous chemotherapy in Crohn's disease: A five year follow up study
32. Comparative in vitro and in vivo activity of rifabutin and rifampicin against Mycobacterium avium complex
33. Activities of clarithromycin, azithromycin and ofloxacin in combination with liposomal or unencapsulated granulocyte-macrophage colony-stimulating factor against intramacrophage Mycobacterium avium - Mycobacterium intracellulare
34. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampicin against Mycobacterium avium complex
35. Activity of seven antimicrobial agents, alone and in combination, against AIDS-associated isolates of Mycobacterium avium complex
36. Antimicrobial activity of rifabutin in combination with two and three other antimicrobial agents against strains of Mycobacterium paratuberculosis
37. Activity of clarithromycin compared with those of other drugs against Mycobacterium paratuberculosis and further enhancement of its extracellular and intracellular activities by ethambutol
38. Effects of clarithromycin alone and in combination on intracellular and extracellular replication of Mycobacterium avium
39. In vitro and ex vivo activities of antimicrobial agents used in combination with clarithromycin, with or without amikacin, against Mycobacterium avium
40. Antimycobacterial synergism of clarithromycin and rifabutin
41. Intracellular accumulation of azithromycin by cultured human fibroblasts
42. In-vitro concentration of azithromycin in human phagocytic cells
43. The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans
44. Two-year outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics
45. A simple index of Crohn's-disease activity
46. Dyspeptic symptoms improve following eradication of gastric Campylobacter pyloridis
47. Cure of duodenal ulcer after eradication of Helicobacter pylori
48. Antibacterial therapy for Crohn's disease: A review emphasizing therapy directed against mycobacteria
49. Acquired resistance in Mycobacterium avium complex strains isolated from AIDS patients and beige mice during treatment with clarithromycin
50. Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy
51. Clarithromycin, rifabutin and clofazimine for treatment of disseminated Mycobacterium avium complex disease in AIDS patients
52. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin-influence on treatment outcome
53. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance
54. Genetic diversity and evidence for acquired antimicrobial resistance in Mycobacterium tuberculosis at a large hospital in South India
55. Activity of rifabutin alone and in combination with clofazimine, kanamycin and ethambutol against Mycobacterium intracellulare infections in mice
56. In vitro activities of rifabutin, azithromycin, ciprofloxacin, clarithromycin, clofazimine, ethambutol and amikacin in combinations of two, three and four drugs against Mycobacterium avium
57. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease
58. Treatment of severe Crohn's disease using rifabutin-macrolide-clofazimine combination: Results at 38-43 months
59. An open pilot study of antimicrobial therapy in patients with unresponsive Crohn's disease